April 03, 2026 02:58 pm (IST)

Make this your homepage

Health

AAP drops Raghav Chadha from key parliamentary role, sparks buzz over internal rift | Amit Shah to camp in West Bengal for 15 days during Assembly polls; predicts Mamata’s defeat in state and Bhabanipur | 'BJP plotting President’s Rule, don’t fall in the trap': Mamata Banerjee on Malda unrest, urges peace | 'Most polarised state': CJI Kant raps Bengal govt over 9-hour hostage of judicial officers | Bengal SIR protest: Judge pleads for help amid mob attack after 9-hour hostage ordeal | Bengal SIR progress: 47 lakh of 60 lakh adjudicated cases disposed of, Supreme Court informed | Amit Shah to join Suvendu Adhikari on Bhabanipur nomination day; BJP plans mega roadshow | Fuel prices rise: Premium petrol, diesel hiked amid oil price surge | Commercial LPG up Rs 195.50 as global oil prices rise; domestic rates unchanged | Layoff alert: Oracle cuts 30,000 jobs globally, 12,000 hit in India

COVID Naval Vaccine

Wikipedia Commons

Covaxin maker's nasal Covid vaccine cleared for emergency use, announces Mansukh Mandaviya

India Blooms News Service | @indiablooms | Sep 06, 2022, at 10:29 pm

New Delhi: Bharat Biotech’s needle-free intranasal vaccine against Covid-19 has gained emergency use approval in India Union health minister Mansukh Mandaviya confirmed on Tuesday.

The Minister said the step will further strengthen India's collective fight against the pandemic.

The vaccine could be delivered through naval route.

This step will further strengthen our collective fight against the pandemic.

India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM @NarendraModi Ji's leadership.

With the science-driven approach & Sabka Prayas, we will defeat COVID-19.
— Dr Mansukh Mandaviya (@mansukhmandviya) September 6, 2022

"Big Boost to India's Fight Against COVID-19! Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation," the Minister tweeted.

Big Boost to India's Fight Against COVID-19!

Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.
— Dr Mansukh Mandaviya (@mansukhmandviya) September 6, 2022

"This step will further strengthen our collective fight against the pandemic. India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM @NarendraModi Ji's leadership. With the science-driven approach & Sabka Prayas, we will defeat COVID-19," he said.

India reported 4,417 new Covid-19 cases while the toll went up by 23 in the last 24 hours, the Union Health Ministry said Tuesday.

In the same span of time, 6,032 Covid-19 patients have recovered from across the country.

The active cases, which now stand at 52,336, forms 0.12% of the total number of infections.

The recovery rate now stands at 98.69%.

Under the national vaccination drive, 213.72 crore anti-Covid vaccine doses have been administered in the country.

#Covaxin #CovaxinNavalVaccine #COVID19

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.